|
1
|
Gijtenbeek RGP, de Jong K, Venmans BJW, van Vollenhoven FHM, Ten Brinke A, Van der Wekken AJ, van Geffen WH. Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Hippokratia 2019. [DOI: 10.1002/14651858.cd013382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Rolof GP Gijtenbeek
- Medical Center Leeuwarden; Department of Pulmonary Diseases; Henri Dunantweg 2 Leeuwarden Netherlands
| | - Kim de Jong
- Medical Center Leeuwarden; Department of Epidemiology; Henri Dunantweg 2 Leeuwarden Friesland Netherlands
| | - Ben JW Venmans
- Medical Center Leeuwarden; Department of Pulmonary Diseases; Henri Dunantweg 2 Leeuwarden Netherlands
| | - Femke HM van Vollenhoven
- Medical Center Leeuwarden; Department of Pulmonary Diseases; Henri Dunantweg 2 Leeuwarden Netherlands
| | - Anneke Ten Brinke
- Medical Center Leeuwarden; Department of Pulmonary Diseases; Henri Dunantweg 2 Leeuwarden Netherlands
| | - Anthonie J Van der Wekken
- University of Groningen, University Medical Center Groningen; Department of Pulmonary Diseases; Hanzeplein 1 Groningen Netherlands
| | - Wouter H van Geffen
- Medical Center Leeuwarden; Department of Pulmonary Diseases; Henri Dunantweg 2 Leeuwarden Netherlands
| |
Collapse
|